Phase I Trial of Anti-CD20, Anti-CD19, Anti-CD22 CAR (CAR20.19.22) T-cells for Relapsed, Refractory B-cell Malignancies

Protocol No
IIT-SHAH-TRIPLE-CAR20-19-22
Principal Investigator
Nirav Shah
Phase
I
Summary
This project is being done to find new ways to treat relapsed and/or refractory blood or lymph cancers.
Description
Phase I Trial of CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL